References
1. Palella FJJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten
GA, et al. Declining morbidity and mortality among patients with advanced
human immunodeficiency virus infection. HIV Outpatient Study
Investigators. N Engl J Med 1998;338:853-60.
2. Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath
C, et al. Randomised placebo-controlled trial of ritonavir in advanced
HIV-1 disease. The Advance HIV Disease Ritonavir Study
Group. Lancet 1998;351:543-9.
3. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier
JS, et al. A controlled trial of two nucleoside analogues plus indinavir
in persons with human immunodeficiency virus infection and CD4 cell
counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group
320 Study Team. N Engl J Med 1997;337:725-33.
4. Van Cleef G, Fisher EJ, Polk RE. Drug interaction potential with inhibitors
of HIV protease. Pharmacotherapy 1997;17:774-8.
5.
interactions in HIV-positive patients initiated on protease inhibitor therapy
(letter). AIDS 1998;12:228-30.
6. von Moltke LL, Greenblatt DY, Grassi JM, Granda BW, Duan SX, Fogelman
SM, et al. Protease inhibitors as inhibitors of human cytochromes
P450: high risk associated with ritonavir. J Clin Pharmacol 1998;38:106-
11.
7. von Moltke LL, Greenblatt DJ, Granda BW, Giancarlo GM, Duan SX,
Daily JP, et al. Inhibition of cytochrome P450 isoforms by nonnucleoside
reverse transcriptase inhibitors. J Clin Pharmacol 2001;41:85-91.
8. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors: a
review for clinicians. JAMA 1997;277:145-53.
9. Barry M, Gibbons S, Back D, Mulcahy F. Protease inhibitors in patients
with HIV disease. Clinically important pharmacokinetic considerations.
Clin Pharmacokinet 1997;32:194-209.
10. Piscitelli SC, Flexner C, Minor JR, Polis MA, Masur H. Drug interactions
in patients infected with HIV. Clin Infect Dis 1996;23:685-93.
11. Barry M, Mulcahy F, Merry C, Gibbons S, Back D. Pharmacokinetics
and potential interactions amongst antiretroviral agents used to treat patients
with HIV infection. Clin Pharmacokinet 1999;36:289-304.
12. Tseng AL, Foisy MM. Management of drug interactions in patients with
HIV. Ann Pharmacother 1997;31:1040-58.
13. Product
monograph. Sustiva (efavirenz).
Squibb Pharma, February 2002.
14. Patrick DM, Strathdee SA, Currie S, Pitchford W, Rekart ML, FitzGerald
M, et al. Incidence
of HIV in the
at: 6th Annual
Canadian Conference on HIV/AIDS Research,
15. Clarke S, Quah S,
Courtney G,
increasing incidence of HIV infection in injecting drug users (IDU) in
Infections,
16. HIV/AIDS
surveillance report.
Prevention, 2001;13:1- 41.
17. Geduld J,
Archibald C. National trends of HIV and AIDS in
18. Henry JA, Hill IR. Fatal interaction between ritonavir and MDMA.
Lancet 1998;352:1751-2.
19. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the
likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet
1997;32:210-58.
20. Jacobs MR, O’Brien Fehr K. Drugs and drug abuse: a reference text.
21. Tucker GT, Lennard MS, Ellis SW, Woods HF, Cho AK, Lin LY, et al.
The demethylenation of methylenedioxymethamphetamine (“ecstasy”)
by debrisoquine hydroxylase (CYP2D6). Biochem Pharmacol 1994;47:
1151-6.
22. Colado MI,
Williams JL,
effects of ‘Ecstasy’ (MDMA) and 3,4 methylenedioxyamphetamine
(MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer
phenotype. Br J Pharmacol 1995;115:1281-9.
23. Kreth K, Kovar K, Schwab M, Zangar UM. Identification of the human
cytochromes P450 involved in the oxidative metabolism of “Ecstasy”-related
drugs. Biochem Pharmacol 2000;15:1563-71.
24. Sherlock K, Wolff K, Hay AW, Conner M. Analysis of illicit ecstasy
tablets: implications for clinical management in the accident and emergency
department. J Accid Emerg Med 1999;16:194-7.
25. Hesse LM, von Moltke LL, Shader RI, Greenblatt DJ. Ritonavir,
efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug
interactions with bupropion. Drug Metab Dispos 2001;29:100-2.
26. Lin LY, Kumagai Y, Hiratsuka A, Narimatsu S, Suzuki T, Funae Y, et al.
Cytochrome P4502D isozymes catalyze the 4-hydroxylation of methamphetamine
enantiomers. Drug Metab Dispos 1995;23:610-4.
27. Geertsen S,
methoxyphenamine and 2-methoxyamphetamine in P4502D6-transfected
cells and cell preparations. Xenobiotica 1995;25:895-906.
28. Lin LY, Di Stefano EW, Schmitz DA, Hsu L, Ellis SW, Lennard MS, et
al. Oxidation of methamphetamine and methylenedioxymethamphetamine
by CYP2D6. Drug Metab Dispos 1997;25:1059-64.
29. Lettieri JT, Fung HL. Dose-dependent pharmacokinetics and hypnotic
effects of sodium gamma-hydroxybutyrate in the rat. J Pharmacol Exp
Ther 1979;208:7-11.
30. Lettieri JT, Fung HL. Absorption and first pass metabolism of 14C-gamma-
hydroxybutyric acid. Res Commun Chem Pathol Pharmacol 1976;
13:425-37.
31. Harrington RD, Woodward JA, Hooton TM, Horn JR. Life-threatening
interactions between HIV-1 protease inhibitors and the illicit drugs
MDMA and gamma-hydroxybutyrate. Arch Intern Med 1999;159:2221-
4.
32. White PF, Way WL, Trevor AJ. Ketamine — its pharmacology and therapeutic
uses. Anesthesiology 1982;56:119-36.
33. Yanagihara Y, Kariya S, Ohtani M, Uchino K, Aoyama T, Yamamura Y,
et al. Involvement of CYP2B6 in n-demethylation of ketamine in human
liver microsomes. Drug Metab Dispos 2001;29:887-90.
34. Loch JM, Potter J, Bachman KA. The influence of anesthetic agents on
rat hepatic cytochromes P450 in vivo. Pharmacology 1995;50:146-53.
35. Menuguz A, Fortuna S, Lorenzini P, Volpe MT. Influence of urethane
and ketamine on rat hepatic cytochrome P450 in vivo. Exp Toxicol
Pathol 1999;51:392-6.
36. Laurenzana EM, Owens SM. Metabolism of phencyclidine by human
liver microsomes. Drug Metab Dispos 1997;25:557-63.
37. Shelnutt SR, Badger TM, Owens SM. Phencyclidine metabolite irreversible
binding in the rat: gonadal steroid regulation and CYP2C11. J
Pharmacol Exp Ther 1996;277:292-8.
38. Crowley JR, Hollenberg PF. Mechanism-based inactivation of rat liver
cytochrome P4502B1 by phencyclidine and its oxidative product, the
iminium ion. Drug Metab Dispos 1995;23:786-93.
39. Inoue T, Niwaguchi T, Murata T. Effects of inducers and/or inhibitors on
metabolism of lysergic acid diethylamide in rat liver microsomes. Xenobiotica
1980;10:913-20.
40. Cai J, Henion J. Elucidation of LSD in vitro metabolism by liquid chromatography
and capillary electrophoresis coupled with tandem mass
spectrometry. J Anal
Toxicol 1996;
41. Iribarne C, Berthou F, Baird S, Dreano Y, Picart D, Bail JP, et al. Involvement
of cytochrome P450 3A4 enzyme in the N-demethylation of
methadone in human liver microsomes. Chem Res Toxicol 1996;9:365-
73.
1610 ■ The Annals of Pharmacotherapy ■ 2002 October, Volume 36 www.theannals.com
T Antoniou and AL Tseng
42. Foster DJ, Somogyi AA, Bochner F. Methadone N-demethylation in human
liver microsomes: lack of stereoselectivity and involvement of
CYP3A4. Br J Clin Pharmacol 1999;47:403-12.
43. Eap CB, Broly F,
P450 2D6 genotype and methadone steady-state concentrations.
J Clin Psychopharmacol 2001;21:229-34.
44. Gerber JG, Rhodes RJ. Cytochrome P450 2B6 metabolizes methadone
preferentially and stereospecifically. An explanation of drug interaction
with antiretroviral drugs (abstract 2.2). Presented at: First International
Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk, the
45. Clarke SM, Mulcahy FM, Tjia J, Reynolds HE, Gibbons SE, Barry MG,
et al. The pharmacokinetics of methadone in HIV-positive patients receiving
the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J
Clin Pharmacol 2001;51:213-7.
46. Heelon MW, Meade LB. Methadone withdrawal when starting an
antiretroviral regimen including nevirapine. Pharmacotherapy 1999;19:471-
2.
47. Marzolini C, Troillet N, Telenti A, Baumann P, Decosterd LA, Eap CB.
Efavirenz decreases methadone blood concentrations. AIDS 2000;14:1291-
2.
48. Pinzani V, Faucherre V, Peyriere H, Blayac JP. Methadone withdrawal
symptoms with nevirapine and efavirenz (letter). Ann Pharmacother
2000;34:405-7.
49. Staszewski S, Haberl A, Gute P, Nisius G, Miller V, Carlebach A.
Nevirapine/didanosine/lamivudine once daily in HIV-1 infected intravenous
drug users. Antiviral
Ther 1998;
50. Altice FL,
Friedland GH, Cooney
among injection drug users with HIV infection receiving
methadone. AIDS 1999;13:957-62.
51. Otero MJ, Fuertes A, Sanchez R, Luna G. Nevirapine-induced withdrawal
symptoms in HIV patients on methadone maintenance programme:
an alert. AIDS 1999;13:1004-5.
52. Geletko SM, Erickson AD. Decreased methadone effect after ritonavir
initiation. Pharmacotherapy 2000;20:93-4.
53. Hsyu PH, Lillibridge JH, Maroldo L, Weiss WR, Kerr BM. Pharmacokinetic
and pharmacodynamic interactions between nelfinavir and methadone
(abstract 87). Presented at: 7th Conference on Retroviruses and Opportunistic
Infections,
54. Gerber JG, Rosenkranz S, Segal Y, Aberg J, D’Amico R, Mildvan D, et
al. The effect of ritonavir/saquinavir on the stereoselective pharmacokinetics
of methadone: results of AIDS clinical trials group (ACTG) 401. J
Acq Immune Def Synd 2001;27:153-60.
55. Hendrix C, Wakeford J, Wire MB, Bigelow G, Cornell E, Christopher J,
et al. Pharmacokinetic and pharmacodynamic evaluation of methadone
enantiomers following co-administration with amprenavir in opioid-dependent
subjects (abstract 1649). Presented at: 40th Interscience Conference
on Antimicrobial
Agents and Chemotherapy,
17–20, 2000:335.
56. Maroldo L, Manocchio S, Artenstein A, Weiss W. Lack of effect of nelfinavir
mesylate on maintenance methadone dose requirement (abstract
WePeB4120). Presented
at: XIII International AIDS Conference,
57. McCance-Katz EF, Farber S, Selwyn PA, O’Connor A. Decrease in
methadone levels with nelfinavir mesylate (letter). Am J Psychiatry
2000;157:481.
58. Beauverie P, Taburet AM, Dessalles MC, Furlan V, Touzeau D. Therapeutic
drug monitoring of methadone in HIV-infected patients receiving
protease inhibitors. AIDS 1998;12:2510-1.
59. Rainey PM, Friedland G, McCance-Katz EF, Andrews L, Mitchell SM,
Charles C, et al. Interaction of methadone with didanosine and stavudine.
J Acq Immune Def Synd 2000;24:241-8.
60. Schwartz EL, Brechbuhl AB, Kahl P, Miller MA, Selwyn PA, Friedland
GH. Pharmacokinetic interactions of zidovudine and methadone in intravenous
drug–using patients with HIV infection. J Acq Immune Def
Synd 1992;5:619-26.
61. McCance-Katz EF, Rainey PM, Jatlow P, Friedland G. Methadone effects
on zidovudine disposition (AIDS clinical trials group 262). J Acq
Immune Def Synd 1998;18:435- 43.
62. Sellers E, Lam R, McDowell J, Corrigan B, Hedayetullah N, Somer G,
et al. The pharmacokinetics of abacavir and methadone following coadministration:
CNAA1012 (abstract 663). Presented at: 39th Interscience
Conference on
Antimicrobial Agents and Chemotherapy,
63. Booker B, Smith P, Forrest A, Difrancesco R, Morse G, Cottone P, et al.
Lack of effect of methadone (MET) on the pharmacokinetics (PK) of
delavirdine (DLV) & N-delavirdine (abstract A 490). Presented at: 41st
Interscience Conference on Antimicrobial Agents and Chemotherapy,
64. Boffito M, Rossati A, Dal Conte I, Reynolds H, Gibbons S, Back D, et
al. Opiate withdrawal syndrome in new efavirenz recipients under
methadone maintenance regimen (abstract). Presented at: 1st IAS Conference
on HIV Pathogenesis
and Treatment,
2001.
65. Smith PF, Booker BM, Difrancesco R, Morse GD, Cottone PF, Murphy
MK, et al. Effect of methadone or LAAM on the pharmacokinetics of
nelfinavir & M8 (abstract A- 491). Presented at: 41st Interscience Conference
on Antimicrobial
Agents and Chemotherapy,
16–19, 2001:14.
66. Brown LS,
concomitantly with methadone is effective and well-tolerated in
HepC co-infected patients (abstract I-206). Presented at: 41st Interscience
Conference on
Antimicrobial Agents and Chemotherapy,
67.
(PK) of once daily (QD) saquinavir/ritonavir (SQV/RTV): effects
on unbound methadone and á-acid glycoprotein (AAG) (abstract
A-492). Presented at: 41st Interscience Conference on Antimicrobial
Agents and Chemotherapy,
68. Clarke SM, Mulcahy FM, Tjia J, Reynolds HE, Gibbons SE, Barry MG,
et al. Pharmacokinetic interactions of nevirapine and methadone and
guidelines for use of nevirapine to treat injection drug users. Clin Infect
Dis 2001;33:1595-7.
69. Cantilena L, McCrea J, Blazes D, Winchell G, Carides A, Royce C, et al.
Lack of a pharmacokinetic interaction between indinavir and methadone
(abstract PI-74). Clin Pharmacol Ther 1999;65:135.
70. Clarke S, Mulcahy F, Bergin C, Reynolds H, Boyle N, Barry MG, et al.
Absence of opioid withdrawal symptoms in patients receiving methadone
and the protease inhibitor lopinavir–ritonavir. Clin Infect Dis 2002;34:
1143-5.
71. Munsiff AV, Patel J. Regimens with once daily ritonavir + Fortovase are
highly effective in PI-experienced HIV-HCV co-infected patients on
methadone (abstract 684). Presented at: 39th Annual Meeting of the Infectious
Diseases Society of
72. Friedland G, Rainey P, Jatlow P, Andrews L, Damle B, McCance-Katz
E. Pharmacokinetics (pK) of didanosine (ddI) from encapsulated enteric
coated bead formulation (EC) vs chewable tablet formulation in patients
(pts) on chronic methadone therapy (abstract TuPeB4548). Presented at:
XIV International
AIDS Conference,
1:402-3.
73. Guibert A, Furlan V, Martino J, Taburet AM. In vitro effect of HIV protease
inhibitors on methadone metabolism (abstract). Presented at: 37th
Interscience Conference on Antimicrobial Agents and Chemotherapy,
74. Hsu A, Granneman
GR, Carothers L, Dennis S, Chiu Y-L,
Ritonavir does not increase methadone exposure in healthy volunteers
(abstract 342). Presented at: 5th Conference on Retroviruses and Opportunistic
Infections,
75. Boulton DW, Arnaud P, DeVane CL. A single dose of methadone inhibits
cytochrome P- 4503A activity in healthy volunteers as assessed by
the urinary cortisol ratio. Br J Clin Pharmacol 2001;51:350-4.
76. Iribarne C, Dreano Y, Bardou LG, Menez JF, Berthou F. Interaction of
methadone with substrates of human hepatic cytochrome P450 3A4.
Toxicology 1997;117:13-23.
77. Wu D, Otton SV, Sproule BA, Busto U, Inaba T, Kalow W, et al. Inhibition
of human cytochrome P450 2D6 (CYP2D6) by methadone. Br J
Clin Pharmacol 1993;35:30-4.
78. Zhang KE, Wu E, Patick AK, Kerr B, Zorbas M, Lankford A, et al. Circulating
metabolites of the human immunodeficiency virus protease inhibitor
nelfinavir in humans: structural identification, levels in plasma,
and antiviral activities. Antimicrob Agents Chemother 2001;45:1086-93.
79. Edwards DJ, Svensson CK, Visco JP, Lalka D. Clinical pharmacokinetics
of pethidine. Clin Pharmacokinet 1982;7:421-33.
80. Zhang J, Burnell JC, Dumaual N, Bosron WF. Binding and hydrolysis of
meperidine by human liver carboxylesterase hCE-1. J Pharmacol Exp
Ther 1999;290:314-8.
81. Piscitelli S,
Rock-Kress D, Bertz R,
on the pharmacokinetics of meperidine and normeperidine. Pharmacotherapy
2000;20:549-53.
Recreational Drug–Antiretroviral Agent Interactions
The Annals of Pharmacotherapy ■ 2002 October, Volume 36 ■ 1611 www.theannals.com
82. Dayer P, Desmeules J, Striberni R. In vitro forecasting of drugs that
may interfere with codeine bioactivation. Eur J Drug Metab Pharmacokinet
1992;17:115-20.
83. Poulsen L, Brosen K, Arendt-Neilsen L, Gram LF, Elbaek K, Sindrup
SH. Codeine and morphine in extensive and poor metabolizers of
sparteine: pharmacokinetics, analgesic effect and side effects. Eur J
Clin Pharmacol 1996;51:289-95.
84. Caraco Y, Tateishi T, Guengerich FP, Wood AJ. Microsomal codeine Ndemethylation:
cosegregation with cytochrome P4503A4 activity. Drug
Metab Dispos 1996;24:761-4.
85. Yue QY, Sawe J. Different effects of inhibitors on the O- and Ndemethylation
of codeine in human liver microsomes. Eur J Clin Pharmacol
1997;1997:41-7.
86. Caraco Y, Sheller J, Wood AJ. Pharmacogenetic determinants of
codeine induction by rifampin: the impact on codeine’s respiratory, psychomotor
and miotic effects. J Pharmacol Exp Ther 1997;281:330-6.
87. Caraco Y, Sheller J, Wood AJ. Pharmacogenetic determination of the
effects of codeine and prediction of drug interactions. J Pharmacol Exp
Ther 1996;278:1165-74.
88. Heiskanen T, Olkkola KT, Kalso E. Effects of blocking CYP2D6 on the
pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol
Ther 1998;64:603-11.
89. Coffman BL, Rios GR, King CD, Tephly TR. Human UGT2B7 catalyzes
morphine glucuronidation. Drug Metab Dispos 1997;25:1-4.
90. Fromm MF, Eckhardt K, Li S, Schanzle G, Hofmann U, Mikus G, et al.
Loss of analgesic effect of morphine due to coadministration of rifampin.
Pain 1997;72:261-7.
91. Osborne R, Joel S, Trew D, Slevin M. Analgesic activity of morphine-
6-glucuronide (letter). Lancet 1988;1:828.
92. Chaisson MA,
Stoneburner RL, Hildebrandt DS,
EE, Jaffe HW. Heterosexual transmission of HIV-1 associated with the
use of smokable freebase cocaine (crack). AIDS 1991;5:1121-6.
93. Edlin BR, Irwin KL, Faruque S, McCoy CB, Word C, Serrano Y, et al.
Intersecting epidemics — crack cocaine use and HIV infection among
inner-city young adults. Multicenter Crack Cocaine and HIV Infection
Study Team. N Engl J Med 1994;331:1422-7.
94. Nuttbrock L, Rosenblum A, Magura S, McQuistion HL, Joseph H. The
association between cocaine use and HIV/STDs among soup kitchen
attendees in
95. Inaba T, Stewart DJ, Kalow W. Metabolism of cocaine in man. Clin
Pharmacol Ther 1978;23:547-52.
96. Cone EJ, Tsadik A, Oyler J, Darwin WD. Cocaine metabolism and urinary
excretion after different routes of administration. Ther Drug Monit
1998;20:556-60.
97. Stewart DJ, Inaba T, Lucassen M, Kalow W. Cocaine metabolism: cocaine
and norcocaine hydrolysis by liver and serum esterases. Clin
Pharmacol Ther 1979;25:464-8.
98. Leduc BW, Sinclair PR, Shuster L, Sinclair JF, Evans JE, Greenblatt
DJ. Norcocaine and N-hydroxynorcocaine formation in human liver
microsomes: role of cytochrome P- 450 3A4. Pharmacology 1993;46:
294-300.
99. Ladona MG, Gonzalez ML, Rane A, Peter RM, de la Torre R. Cocaine
metabolism in human fetal and adult liver microsomes is related to cytochrome
P450 3A expression. Life Sci 2000;68:431- 43.
100. Hoffman RS, Henry GC, Howland MA, Weisman RS, Weil L, Goldfrank
LR. Association between life-threatening cocaine toxicity and
plasma cholinesterase activity. Ann Emerg Med 1992;21:247-53.
101. Ndikum-Moffor FM, Schoeb TR, Roberts SM. Liver toxicity from norcocaine
nitroxide, an N-oxidative metabolite of cocaine. J Pharmacol
Exp Ther 1998;284:413-9.
102. Roberts SM,
metabolism of cocaine. Drug Metab Dispos 1991;19:1046-51.
103. Pellinen P, Honkakoski P, Stenback F, Niemitz M, Alhava E, Pelkonen
O, et al. Cocaine N-demethylation and the metabolism-related hepatotoxicity
can be prevented by cytochrome P450 3A inhibitors. Eur J
Pharmacol 1994;270:35- 43.
104. Lockridge O, Mottershaw-Jackson N, Eckerson HW, La Du BN. Hydrolysis
of diacetylmorphine (heroin) by human serum cholinesterase. J
Pharmacol Exp Ther 1980;21:1-8.
105. Inturrisi CE, Max MB, Foley KM, Schultz M, Shin SU, Houde RW.
The pharmacokinetics
of heroin in patients with chronic pain.
Med 1984;310:1213-7.
106. Kamendulis LM, Brzezinski MR, Pindel EV, Bosron WF, Dean RA.
Metabolism of cocaine and heroin is catalyzed by the same human liver
carboxylesterases. J Pharmacol Exp Ther 1996;279:713-7.
107. Jenkins AJ, Keenan RM, Henningfield JE, Cone EJ. Pharmacokinetics
and pharmacodynamics of smoked heroin. J Anal Toxicol 1994;18:317-
30.
108. Busto UE. Benzodiazepines: the science and the myths. Can J Clin
Pharmacol 1999;6:185-6.
109. Kronback T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. Oxidation
of midazolam and triazolam by human liver cytochrome P450IIIa4.
Mol Pharmacol 1989;36:89-96.
110. Venkatakrishnan K, Greenblatt DJ, von Moltke LL, Shader RI. Alprazolam
is another substrate for human cytochrome P450-3A isoforms
(letter). J Clin Psychopharmacol 1998;18:256.
111. Frye R, Bertz R, Granneman GR, Qian J, Lamm J, Dennis S, et al. Effect
of ritonavir on the pharmacokinetics and pharmacodynamics of alprazolam
(abstract A59). Presented at: 37th Interscience Conference on
Antimicrobial Agents
and Chemotherapy,
1, 1997.
112. Greenblatt D, Moltke L, Harmatz J, Durol AL, Daily JP, Graf JA, et al.
Alprazolam–itonavir interaction: implications for product labeling. Clin
Pharmacol Ther 2000;67:335- 41.
113. Palkama VJ, Ahonen J, Neuvonen PJ, Olkkola KT. Effect of saquinavir
on the pharmacokinetics and pharmacodynamics of oral and intravenous
midazolam. Clin Pharmacol Ther 1999;66:33-9.
114. Merry C, Mulcahy F, Barry M, Gibbons S, Back D. Saquinavir interaction
with midazolam: pharmacokinetic considerations when prescribing
protease inhibitors for patients with HIV disease (letter). AIDS 1997;11:
268-9.
115. Greenblatt DJ, von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf
JA, et al. Differential impairment of triazolam and zolpidem clearance
by ritonavir. J Acq Immune Def Synd 2000;24:129-36.
116. Greenblatt DJ, von Moltke LL, Daily JP, Harmatz JS, Shader RI. Extensive
impairment of triazolam and alprazolam clearance by short-term
low-dose ritonavir: the clinical dilemma of concurrent inhibition and
induction. J Clin Psychopharmacol 1999;19:293-6.
117. Seree EJ, Pisano PJ, Placidi M, Rahmani R, Barra YA. Identification of
the human and animal hepatic cytochromes P450 involved in clonazepam
metabolism. Fundam Clin Pharmacol 1993;7:69-75.
118. Hesse LM, Venkatakrishnan K, von Moltke LL, Shader RI, Greenblatt
DJ. CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation
and demethylation of flunitrazepam. Drug Metab Dispos 2001;29:
133- 40.
119. Ono S, Hatanaka T, Miyazawa S, Tsutsui M, Aoyama T, Gonzalez FJ,
et al. Human liver microsomal diazepam metabolism using cDNA expressed
cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily.
Xenobiotica 1996;26:1155-66.
120. Jung F,
by cDNA-expressed human 2C P450s: identification of P4502C18 and
P4502C19 as low K(M) diazepam N-demethylases. Drug Metab Dispos
1997;25:133-9.
121. Patwardhan RV, Yarborough GW, Desmond PV, Johnson RF, Schenker
S, Speeg KVJ. Cimetidine spares the glucuronidation of lorazepam and
oxazepam. Gastroenterology 1980;79:912-6.
122. Ghabrial H, Desmond PV, Watson KJ, Gijsbers AJ, Harman PJ, Breen
KJ, et al. The effects of age and chronic liver disease on the elimination
of temazepam. Eur J Clin Pharmacol 1986;30:93-7.
123. Health
124. Lemberger L. Tetrahydrocannabinol metabolism in man. Drug Metab
Dispos 1972;1:461-8.
125. Lemberger L, Weiss JL, Watanabe AM, Galanter IM, Wyatt RJ, Cardon
PV. Delta-9-tetrahydrocannabinol. Temporal correlation of the psychologic
effects and blood levels after various routes of administration. N
Engl J Med 1972;30:685-8.
126. Bornheim LM, Lasker JM, Raucy JL. Human hepatic microsomal metabolism
of delta 1-tetrahydrocannabinol. Drug Metab Dispos 1992;20:
241-6.
127. Watanabe K, Matsunaga T, Yamamoto I, Funae Y, Yoshimura H. Involvement
of CYP2C in the metabolism of cannabinoids by human hepatic
microsomes from an old woman. Biol Pharm Bull 1995;18:1138-
41.
128. Kosel BW, Aweeka FT, Benowitz NL, Shade SB, Hilton JF, Lizak PS,
et al. The effects of cannabinoids on the pharmacokinetics of indinavir
and nelfinavir. AIDS 2002;16:543-50.
129. McDowell JA, Chittick GE, Pilati-Stevens C, Edwards KD, Stein DS.
Pharmacokinetic interaction of abacavir (1592U89) and ethanol in human
immunodeficiency virus–infected adults. Antimicrob Agents
Chemother 2000;44:1686-90.
1612 ■ The Annals of Pharmacotherapy ■ 2002 October, Volume 36 www.theannals.com
T Antoniou and AL Tseng
Recreational Drug–Antiretroviral Agent Interactions
The Annals of Pharmacotherapy ■ 2002 October, Volume 36 ■ 1613 www.theannals.com
130. Tanaka E, Misawa S. Pharmacokinetic interactions between acute alcohol
ingestion and single doses of benzodiazepines, and tricyclic and
tetracyclic antidepressants — an update. J Clin Pharm Ther 1998;23:
331-6.
131. Klotz U, Ammon E. Clinical and toxicological consequences of the inductive
potential of ethanol. Eur J Clin Pharmacol 1998;54:7-12.
132. Kostrubsky VE, Strom SC, Wood SG, Wrighton SA, Sinclair PR, Sinclair
JF. Ethanol and isopentanol increase CYP3A and CYP2E in primary
cultures of human hepatocytes. Arch Biochem Biophys
1995;322:516-20.
133. Hsu A, Bertz R, Granneman GR. Assessing ritonavir dose effect on the
pharmacokinetic parameters of protease inhibitors (abstract 3.3). Presented
at: 2nd International Workshop on Clinical Pharmacology of
HIV Therapy,
Noordwijk, the
134. Degen O, Kurowski M, Van Lunzen J, Schewe CK, Stellbrink H. Amprenavir
and ritonavir: intraindividual comparison of different doses
and influence of concomitant NNRTI on steady-state pharmacokinetics
in HIV-infected patients (abstract 739). Presented at: 8th Conference on
Retroviruses and
Opportunistic Infections,
2001:267.